(7ci,8ci)-1H-氮杂卓-1-羧酰胺 | 3342-22-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吖庚因类
• 中文名称: (7ci,8ci)-1H-氮杂卓-1-羧酰胺
• 英文名称: N-Carbamylazepin
• 英文别名: 1-Carbamoyl-1H-azepin；azepine-1-carboxylic acid amide；azepine-1-carboxamide；1H-Azepine-1-carboxamide
• CAS: 3342-22-1
• 化学式: C₇H₈N₂O
• mdl: MFCD18807230
• 分子量: 136.153
• InChiKey: WYVODKWLXXDREA-UHFFFAOYSA-N

物化性质

• 沸点：
  277.2±23.0 °C(Predicted)
• 密度：
  1.198±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  46.3
• 氢给体数：
  1
• 氢受体数：
  1

安全信息

• 海关编码：
  2933990090

文献信息

• [EN] COMPOUNDS AND METHODS FOR TREATING DYSLIPIDEMIA<br/>[FR] COMPOSES ET TECHNIQUES DE TRAITEMENT DE LA DYSLIPIDEMIE
  申请人：LILLY CO ELI

  公开号：WO2005037796A1

  公开（公告）日：2005-04-28

  Compounds of formula I wherein n, m, p, q, Y, R1 R2, R3, R4, R5, and R6 are as defined herein and their pharmaceutical compositions and methods of use are disclosed as useful for treating artherosclerosis and its sequelae.

  式I的化合物，其中n、m、p、q、Y、R1、R2、R3、R4、R5和R6如本文所定义，并且其药物组合物和使用方法被披露为用于治疗动脉粥样硬化及其后遗症。
• [EN] SUBSTITUTED QUINOLINE CCR5 RECEPTOR ANTAGONISTS<br/>[FR] ANTAGONISTES DU RECEPTEUR CCR5 A BASE DE QUINOLEINE SUBSTITUES
  申请人：SCHERING AG

  公开号：WO2004002960A1

  公开（公告）日：2004-01-08

  The present invention relates to CCR5 receptor antagonists of formulae (1a) or (1b), enantiomers, diastereomers, salts and solvates thereof wherein R1, R2, R3, R4, R5, and R7 are as defined herein. The invention further includes a method of CCR5-mediated disorders employing such compounds.

  本发明涉及式（1a）或（1b）的CCR5受体拮抗剂，其对映体、二对映体、盐和溶剂合物，其中R1、R2、R3、R4、R5和R7如本文所定义。该发明还包括一种利用这些化合物治疗CCR5介导的疾病的方法。
• Therapeutic method for treating patients with acute intermittent porphyria (AIP) and other porphyric diseases
  申请人：——

  公开号：US20030223979A1

  公开（公告）日：2003-12-04

  A method for treatment or prophylaxis of disease caused by deficiency, in a subject, of an enzyme belonging to the heme biosynthetic pathway, the method comprising administering, to the subject, an effective amount of a catalyst which is said enzyme or an enzymatically equivalent part or analogue thereof. The disease is selected from the group consisting of acute intermittent porphyria (AIP), ALA deficiency porphyria (ADP), Porphyria cutanea tarda (PCT), Hereditary coproporphyria (HCP), Harderoporphyria (HDP), Variegata porphyria (VP), Congenital erythropoetic porphyria (CEP), Erythropoietic protoporphyria (EPP), and Hepatoerythropoietic porphyria (HEP). The catalyst is one or more enzymes selected from the group consisting of delta-aminolevulininic acid synthetase, delta-aminolevulinic acid dehydratase (ALAD), porphobilinogen deaminase (PBGD), uroporphyrinogen III cosythetase, uroporphyrinogen decarboxylase, coproporphyrinogen oxidase, protoporphyrinogen oxidase, and ferrochelatase, or an enzymatically equivalent part or analogue thereof. In addition the invention relates to the use of PBGD, to human recombinant PBGD and to a method of gene therapy. The invention also relates to an expression plasmid pExp1-M2-BB (Seq. ID No. 1) and to use of a DNA fragment, the EcoR I-Hind III linear fragment (seq. ID No. 2), used for transformation in the hemC disruption strategy for production of rhPBGD expressed in E. coli.

  一种治疗或预防受试者因缺乏属于血红素生物合成途径的酶而引起的疾病的方法，该方法包括向受试者施用有效量的催化剂，该催化剂为所述酶或其酶等效部分或类似物。所述疾病选自急性间歇性 卟啉症 (AIP)、ALA 缺乏症 卟啉症 (ADP）、 卟啉症 卟啉症（PCT）、遗传性共卟啉症（HCP）、硬卟啉症（HDP）、 变性卟啉症 （VP）、先天性红细胞生成性 卟啉症 (CEP）、 红细胞生成性原卟啉症（EPP (EPP) 和 肝红细胞生成性卟啉症（HEP (HEP）。 催化剂是选自δ-氨基乙酰丙酸合成酶、δ-氨基乙酰丙酸脱水酶（ALAD）、卟啉原脱氨酶（PBGD）、尿卟啉原 III 合成酶、尿卟啉原脱羧酶、共卟啉原氧化酶、原卟啉原氧化酶和铁螯合酶或其酶等效部分或类似物组成的组中的一种或多种酶。此外，本发明还涉及 PBGD 的使用、人重组 PBGD 以及基因治疗方法。本发明还涉及一种表达质粒 pExp1-M2-BB（Seq.ID No.1）和 DNA 片段的使用，即 EcoR I-Hind III 线性片段（seq.ID No.2），用于在 hemC 干扰策略中进行转化，以生产在大肠杆菌中表达的 rhPBGD。 大肠杆菌。
• TREATMENT OF ACUTE INTERMITTENT PORPHYRIA (AIP) AND OTHER PORPHYRIC DISEASES
  申请人：Hemebiotech A/S

  公开号：EP1049487B1

  公开（公告）日：2002-05-22
• METHOD FOR TREATING ACUTE INTERMITTENT PORPHYRIA (AIP) AND OTHER PORPHYRIC DISEASES
  申请人：Hemebiotech A/S

  公开号：EP1049487A2

  公开（公告）日：2000-11-08